Is diabetic nephropathy disappearing from clinical practice?

Pediatric Diabetes

Volumn 7, Issue 5, 2006, Pages 237-238

  Cooper, Mark E ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLYCOSYLATED PROTEIN; INSULIN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RENIN; RENIN INHIBITOR;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; DENMARK; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; EDITORIAL; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; NORWAY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT REFERRAL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; URINALYSIS;

DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HUMANS; INCIDENCE; PROGNOSIS; RISK ASSESSMENT;

EID: 33750138330     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2006.00205.x     Document Type: Editorial

References (15)

1. Cooper ME. Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 1998: 352: 213-219.
2. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type I (insulin-dependent) diabetes mellitus. Diabetologia 1985: 28: 590-596.
3. Skrivarhaug T, Bangstad H-J, Stene LC, Sandvik L, Hanssen KF, Joner G. Low risk of overt nephropathy after 24 yr of childhood-onset type 1 diabetes mellitus (T1DM) in Norway. Pediatr Diabetes 2006: 7: 239-246.
4. Andersen AR, Christiansen JS, Anderson JK, Kreiner S, Deckert T. Diabetic nephropathy in type I (insulin-dependent) diabetes: An epidemiological study. Diabetologia 1983: 25: 496-501.
5. Hovind P, Tarnow L, Rossing K et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003: 26: 1258-1264.
6. Sorensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int 2006: 70: 187-191.
7. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003: 348: 383-393.
8. Hovind P, Tarnow L, Rossing P et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004: 328: 1105.
9. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
10. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001: 134: 370-379.
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993: 329: 1456-1462.
12. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003: 361: 2005-2016.
13. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001: 44: 1957-1972.
14. Thomas MC, Tikellis C, Burns WM et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005: 16: 2976-2984.
15. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001: 414: 813-820.